1350PPhase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI